AbCellera Biologics Inc. (ABCL) Reports Q4 Loss, Tops Revenue Estimates
ABCELLERA BIOLG (ABCL) delivered earnings and revenue surprises of +83.56% and +565.48%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?